Teva Emerges From Restructuring Ready To Grow
Captures 12%-15% Rituximab Share In US With Truxima Biosimilar
Executive Summary
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
You may also be interested in...
Teva CEO Schultz To Sign On For Another Year
Teva CEO Kåre Schultz has received full backing to add another year onto his five-year contract, with a significant rise in compensation available if Teva’s shareholders say so later this year.
Teva Sticks With 10% Discount For Trastuzumab
Teva and Celltrion have launched their Herzuma trastuzumab biosimilar in the US at a 10% discount to the Herceptin brand. The discount matches that offered for their Truxima rituximab biosimilar and compares to steeper discounts offered by competing biosimilars.
Pfizer’s US Rituximab Launched At A 24% Discount
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: